SAN FRANCISCO--(BUSINESS WIRE)--ReSync Bio, a scientific software provider accelerating preclinical R&D, today announced the company’s launch and a fundraise from Caffeinated Capital, Atria Ventures and leading angel investors including Ramsey Homsany, co-founder of Octant Bio. The company will use the funds to make key hires and commercialize their platform, which is now available for use by companies and academics..

旧金山——（商业新闻短讯）——ReSync Bio是一家加速临床前研发的科学软件提供商，今天宣布公司成立，并从咖啡因资本、Atria Ventures和领先的天使投资者（包括Octant Bio的联合创始人拉姆齐·霍姆桑尼）那里筹集资金。该公司将利用这些资金进行关键招聘并将其平台商业化，该平台目前可供公司和学术界使用。。

Preclinical drug discovery today is slowed by numerous bottlenecks. Disconnected software tools make it difficult to coordinate data across various computational models, in-house labs, and contract research organizations (CROs). Disorganized and siloed data makes adopting modern AI tooling difficult.

今天的临床前药物发现因许多瓶颈而减慢。断开连接的软件工具使得跨各种计算模型、内部实验室和合同研究组织（CRO）协调数据变得困难。杂乱无章和孤立的数据使得采用现代人工智能工具变得困难。

This forces pharmaceutical and biotechnology companies to keep reinventing the data engineering wheel with bespoke solutions that take time and resources away from their science..

这迫使制药和生物技术公司不断用定制的解决方案重新发明数据工程轮子，这些解决方案占用了他们的科学时间和资源。。

“Our mission is to accelerate drug discovery programs across the industry,” said ReSync Founder and CEO Mihir Trivedi. “AI advances in generative drug discovery have transformed throughput on the digital side, but major challenges remain in translating this progress to the experimental side of the life sciences, where it takes far too long to go from idea to assay data.

ReSync创始人兼首席执行官米希尔·特里维迪（MihirTrivedi）表示：“我们的使命是加速整个行业的药物发现计划。”。“人工智能在生成性药物发现方面的进步已经改变了数字方面的吞吐量，但将这一进展转化为生命科学实验方面仍然存在重大挑战，从想法到分析数据需要很长时间。

ReSync is a bridge that synergizes the digital and experimental worlds to help bring therapeutics to the clinic faster.”.

ReSync是一座桥梁，它可以协同数字和实验世界，帮助更快地将治疗方法带到诊所。”。

ReSync was inspired by Trivedi’s tenure as an early engineer at PostEra, where he saw firsthand the need for more standard tooling in AI-driven drug discovery. ReSync’s platform is designed to help companies organize and train their data, models, and experimental workflows more efficiently.

ReSync的灵感来自Trivedi在PostEra担任早期工程师的任期，在那里他亲眼看到了在人工智能驱动的药物发现中需要更标准的工具。ReSync的平台旨在帮助公司更有效地组织和培训其数据、模型和实验工作流程。

“The reality in the lab today is that AI drug discovery programs are hindered by uncoordinated experiments and unstructured data,” said Chris Leiter of Atria Ventures. “ReSync is a universal tool that any life sciences company can use to eliminate preclinical bottlenecks and make their data work smarter.

Atria Ventures的克里斯·莱特（ChrisLeiter）说：“今天实验室的现实是，人工智能药物发现计划受到不协调的实验和非结构化数据的阻碍。”。“ReSync是一种通用工具，任何生命科学公司都可以使用它来消除临床前瓶颈，并使其数据工作更智能。

ReSync is the essential automation layer of the life sciences that makes AI bioacceleration possible.”.

ReSync是生命科学必不可少的自动化层，它使AI生物加速成为可能。”。

ReSync’s platform automates coordination between drug discovery teams and their labs - whether they be in-house or external CROs. The software includes tightly controlled permissioning that lets companies control data access and promote collaboration while protecting IP.

ReSync的平台自动化了药物发现团队与其实验室之间的协调，无论是内部还是外部CRO。该软件包括严格控制的许可，允许公司控制数据访问并促进协作，同时保护IP。

“Companies like Microsoft and NVIDIA are investing billions in AI-powered drug discovery platforms and services, but there’s still a huge unmet need for better data infrastructure to realize the potential of these technologies,” said Varun Gupta of Caffeinated Capital. “We believe ReSync can become a keystone of the AI drug discovery space that enables hundreds of other companies to bring lifesaving therapeutics to market.”.

咖啡因资本的瓦伦·古普塔（VarunGupta）表示：“微软（Microsoft）和英伟达（NVIDIA）等公司正在投资数十亿美元用于人工智能（AI）驱动的药物发现平台和服务，但对更好的数据基础设施的巨大需求仍未得到满足，以实现这些技术的潜力。”。“我们相信ReSync可以成为人工智能药物发现领域的基石，使数百家其他公司能够将救生疗法推向市场。”。

“ReSync’s goal is to make therapeutics companies more efficient, so they make decisions faster and ultimately bring therapies to the clinic – and patients – quickly,” added Trivedi.

。

About ReSync Bio

关于ReSync生物

ReSync Bio is a scientific software company that makes tools to help biopharma companies accelerate their drug discovery operations. The company’s SaaS product serves as a single source of truth for preclinical data, helping customers coordinate their programs across labs and CROs and ultimately bring drugs to the clinic more efficiently.

ReSync Bio是一家科学软件公司，生产工具以帮助生物制药公司加速其药物发现业务。该公司的SaaS产品作为临床前数据的单一真实来源，帮助客户在实验室和CRO之间协调他们的计划，并最终更有效地将药物带到诊所。

ReSync’s headquarters is in San Francisco, CA. Visit https://resync.bio/ to learn more..

ReSync的总部位于加利福尼亚州旧金山https://resync.bio/要了解更多。。